Alzheimer's: still watching the pipeline
Anti-amyloid therapy is now a routine option in selected patients; the next mechanism class is the open question.
Alzheimer's care has changed. Anti-amyloid therapy is now a routine option for selected patients, with biomarker confirmation and infusion-centre delivery part of the pathway. What the next mechanism class looks like is the open question.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is spasticity?
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedAcute ischemic stroke explained
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.